An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 4115-4128

  Bae, Jeong A ^a   Yoon, Somy ^a   Park, So Yeon ^a   Lee, Jae Hyuk ^a   Hwang, Jun Eul ^a   Kim, Hangun ^b   Seo, Young Woo ^c   Cha, Yoon Jin ^d   Hong, Sung Pil ^d   Kim, Hoguen ^d   Chung, Ik Joo ^a   Kim, Kyung Keun ^a  

^a Chonnam National University Medical School   (South Korea)

^b Sunchon National University   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD82 ANTIGEN; CETUXIMAB; DISHEVELLED 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KAI1 CARBOXY TERMINAL INTERACTING TETRASPANIN; PROTEIN C JUN; TETRASPANIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DISHEVELLED PROTEINS; EGFR PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR MARKER; VANGL1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER TISSUE; COLON CARCINOGENESIS; COLON METASTASIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; APOPTOSIS; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84905495771     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2863     Document Type: Article

References (36)

1. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-67.
2. Huang Z, Brdlik C, Jin P, Shepard HM. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 2009;9:97-110.
3. Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 2010;59:838-58.
4. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuxmab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
5. Van Cutsem E, Borras JM, Castells A, Ciardiello F, Ducreux M, Haq A, et al. Improving outcomes in colorectal cancer: where do we go from here? Eur J Cancer 2013;49:2476-85.
6. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013;85:45-81.
7. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009;4:e7287.
8. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93.
9. Lee JH, Park SR, Chay KO, Seo YW, Kook H, Ahn KY, et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res 2004;64:4235-43.
10. Lee JH, Cho ES, Kim MY, Seo YW, Kho DH, Chung IJ, et al. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein. Cancer Res 2005;65:8993-9003.
11. Kho DH, Bae JA, Lee JH, Cho HJ, Cho SH, Lee JH, et al. KITENIN recruits Dishevelled/PKCd to form a functional complex and controls the migration and invasiveness of colorectal cancer cells. Gut 2009;58:509-19.
12. Lee S, Song YA, Park YL, Cho SB, Lee WS, Lee JH, et al. Expression of KITENIN in human colorectal cancer and its relation to tumor behavior and progression. Pathol Int 2011;61:210-20.
13. Lee JK, Lim SC, Kim HD, Yoon TM, Kim K, Nam JH, et al. KITENIN represents a more aggressive phenotype in a murine model of oral cavity squamous carcinoma. Otolaryngol Head Neck Surg 2010;142:747-52.
14. Lee JK, Yoon TM, Seo DJ, Sun EG, Bae JA, Lim SC, et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN) expression in early and advanced laryngeal cancer. Laryngoscope 2010;120:953-8.
15. Yoon TM, Kim SA, Lee JK, Park YL, Kim GY, Joo YE, et al. Expression of KITENIN and its association with tumor progression in oral squamous cell carcinoma. Auris Nasus Larynx 2013;40:222-6.
16. Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, et al. KITENIN is associated with tumor progression in human gastric cancer. Anticancer Res 2010;30:3479-86.
17. Cho SB, Park YL, Park SJ, Park SY, Lee WS, Park CH, et al. KITENIN is associated with activation of AP-1 target genes via MAPK cascades signaling in human hepatocellular carcinoma progression. Oncol Res 2011;19:115-23.
18. Li L, Yuan H, Xie W, Mao J, Caruso AM, McMahon A, et al. Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun. N-terminal kinase in mammalian cells. J Biol Chem 1999;274:129-34.
19. Wiley HS, Walsh BJ, Lund KA. Global modulation of the epidermal growth factor receptor is triggered by occupancy of only a few receptors: evidence for a binary regulatory system in normal human fibroblasts. J Biol Chem 1989;264:18912-20.
20. Egeblad M, Mortensen OH, Van Kempen LC, Jaüüattelaü M. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells. Biochem Biophys Res Commun 2001;281:25-31.
21. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
22. Davies CC, Chakraborty A, Cipriani F, Haigh K, Haigh JJ, Behrens A. Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activation. Nat Cell Biol 2010;12:963-72.
23. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013;2:e71.
24. Ding W, Li C, Hu T, Graves-Deal R, Fotia AB, Weissman AM, et al. EGF receptor-independent action of TGF-alpha protects Naked2 from AO7-mediated ubiquitylation and proteasomal degradation. Proc Natl Acad Sci U S A 2008;105:13433-8.
25. Li Z, Jin K, Lan H, Teng L. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? Hepatogastroenterology 2011;58:411-6.
26. Yu SY, Liu HF, Wang SP, Chang CC, Tsai CM, Chao JI. Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact 2013;203:412-22.
27. Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ, et al. Inhibition of TGF-b enhances the in vivo antitumor efficacy of EGF receptortargeted therapy. Mol Cancer Ther 2012;11:2429-39.
28. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007;26:1-10.
29. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun. with TCF4 regulates intestinal cancer development. Nature 2005;437:281-85.
30. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun. N-terminal kinases. Microbiol Mol Biol Rev 2006;70:1061-95.
31. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010;661:3-38.
32. Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 2012;12:387-400.
33. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, et al. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 2005;280:30392-9.
34. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 2010;464:783-7.
35. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
36. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-65.